Eledon Pharmaceuticals Inc (ELDN)
Healthcare
Biotechnology
3.40 $
-0.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Eledon Pharmaceuticals Inc (ELDN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.6% of the shares are freely tradable; institutional investors hold 59.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
59.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
90.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
77Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Bvf Inc | 8.15 | 6,293,282 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.68 | 4,382,245 | +20.8 | 03/31/2026 |
| Vanguard Group Inc | 5.23 | 4,039,686 | +23.6 | 12/31/2025 |
| Defilade Capital Management, L.P. | 4.62 | 3,564,127 | +8.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.27 | 3,293,134 | +0.0 | 03/31/2026 |
| Ensign Peak Advisors Inc | 3.19 | 2,464,919 | +0.0 | 03/31/2026 |
| Zimmer Partners LP | 2.43 | 1,875,000 | -21.4 | 03/31/2026 |
| Geode Capital Management, LLC | 2.32 | 1,791,783 | +26.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.05 | 2,356,062 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 2.34 | 1,807,231 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.